[(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-butanoyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-butanoyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate
• 化学式: C₄₉H₇₂O₁₇
• 分子量: 933.1
• InChiKey: LQRPMEWTGMHDBC-IGZACUPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  66
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  240
• 氢给体数：
  4
• 氢受体数：
  17

文献信息

• [EN] PRODRUGS OF HYDROXYL-COMPRISING DRUGS<br/>[FR] PROMÉDICAMENTS DE MÉDICAMENTS COMPRENANT DES GROUPES HYDROXYLE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013160340A1

  公开（公告）日：2013-10-31

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L1 represented by formula (I) and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer and Z is a carrier group. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药学上可接受的盐，包括生物活性基团-连接物D-L的共轭物，其中D是含有羟基的生物活性基团；L是包含由式(I)表示的基团L1的前基团，其中L1被一个到四个基团L2-Z取代，并且可选择进一步取代，前提是式(I)中带星号标记的氢未被取代；其中L2是一个化学键或一个间隔物，Z是一个载体基团。该发明还涉及包含所述前药的药物组合物及其作为药物的用途。
• Bryostatins
  申请人：ARIZONA BOARD OF REGENTS

  公开号：EP0264173A2

  公开（公告）日：1988-04-20

  New and exceptionally potent antineoplastic agents denominated Bryostatin 9, Bryostatin 10, Bryostatin 11, Bryostatin 12 and Bryostatin 13 have been isolated from the marine animal Bugula neritina (Linneaeus) (Bryozoan phylum) and the structures identified. Meaningful antineoplastic activity is found for each.

  从海洋动物 Bugula neritina（Linneaeus）（毛霉菌门）中分离出了新型特效抗肿瘤物质，分别称为 Bryostatin 9、Bryostatin 10、Bryostatin 11、Bryostatin 12 和 Bryostatin 13，并确定了其结构。每种物质都具有重要的抗肿瘤活性。
• PRODRUGS OF HYDROXYL-COMPRISING DRUGS
  申请人：Ascendis Pharma A/S

  公开号：EP2841109A1

  公开（公告）日：2015-03-04
• US4833257A
  申请人：——

  公开号：US4833257A

  公开（公告）日：1989-05-23
• [EN] METHOD OF TREATING CANCER USING C-26 MODIFIED BRYOSTATIN<br/>[FR] METHODE DE TRAITEMENT DU CANCER AU MOYEN D'UNE BRIOSTATINE MODIFIEE EN POSITION C-26
  申请人：THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：WO1997034598A1

  公开（公告）日：1997-09-25

  (EN) The present invention provides a method of treating cancer in an animal comprising administering to an animal afflicted with cancer a therapeutically effective amount of a bryostatin which has been modified at the C-26 position.(FR) Méthode permettant de traiter un cancer chez un animal en lui administrant une quantité efficace sur le plan thérapeutique de briostatine modifiée en position C-26.